31 Mar
2019

The ITC as a forum for biologic and biosimilar patent disputes

While US biologics patent litigation has been largely confined to district courts, things may be about to change. Offering a number of advantages to innovators, International Trade Commission proceedings are likely to prove increasingly popular with biologics rights holders

Tony V Pezzano

Partner

DLA Piper

Michael P Dougherty

Partner

DLA Piper